Androgen News and Research

RSS

EMUC discusses current and future prospects in imaging for prostate cancer

At the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) held this weekend in Barcelona, Spain, specialists from radiology, urology, medical oncology and pathology said that new developments and research are already underway but benefits to patients would take some time due to the need for clinical trials, the high cost of funding research and the ability of cancer experts to efficiently take advantage of new insights and approaches, among other challenges.

19 Nov 2012

Study identifies genetic variations as predictors of prostate cancer-related fatigue

Researchers at Moffitt Cancer Center and the University of South Florida have found that men with prostate cancer who receive androgen deprivation therapy may predictably suffer from fatigue if they have single nucleotide polymorphisms in three pro-inflammatory genes. The discovery highlights the importance of personalized medicine, in which therapies are tailored to a patient's genetic profile.

29 Oct 2012

New biomarker measures aggressiveness of primary prostate tumors

Research out of Roswell Park Cancer Institute (RPCI) supports the adoption of a new biomarker to measure the aggressiveness of primary prostate tumors.

24 Oct 2012

First report of androgen-dependence of exercise on nerve regeneration

A study by researchers from Emory University and Indiana University found that the beneficial effects daily exercise can have on the regeneration of nerves also require androgens such as testosterone in both males and females. It is the first report of both androgen-dependence of exercise on nerve regeneration and of an androgenic effect of exercise in females.

16 Oct 2012

UCSF project to explore mystery behind advanced prostate cancer

Many men survive prostate cancer, but thousands of others -- whose cancer spreads -- inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.

10 Oct 2012

PARP-1 plays a major role in controlling AR function in prostate cancer patients

A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson's Kimmel Cancer Center researchers suggests.

10 Oct 2012

Data from GTx's enobosarm Phase IIb study on cancer to be presented at SIOG meeting

GTx, Inc. announced today there will be two scientific poster presentations on the effects of enobosarm, a selective androgen receptor modulator (SARM), on improving physical function and quality of life in middle aged and elderly cancer patients.

8 Oct 2012

Hormone and androgen receptor genes combined affect sperm motility

The combination of alleles for genes encoding the follicle-stimulating hormone receptor and androgen receptor has a significant impact on sperm motility, emphasising the importance of the genes in sperm quality, say Greek scientists.

1 Oct 2012

Active Biotech, Ipsen announce new data on biomarkers from tasquinimod Phase II study in CRPC

Active Biotech and Ipsen have presented a new set of data on biomarkers from the previously concluded tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific congress ESMO (European Society for Medical Oncology) held in Vienna September 28-October 2.

1 Oct 2012

September issue of JNCCN publishes two prostate cancer articles

Julio M. Pow-Sang, M.D., chair of Moffitt Cancer Center's Department of Genitourinary Oncology, and colleagues have published two prostate cancer articles in the September issue of JNCCN - The Journal of the National Comprehensive Cancer Network. The articles review and clarify recent updates made to the National Comprehensive Cancer Network's (NCCN) guidelines for the screening and treatment of prostate cancer.

29 Sep 2012

First Edition: September 28, 2012

Today's headlines include reports about political and policy-oriented health care developments.

28 Sep 2012

Anti-androgen therapies may benefit bladder cancer patients

Bladder cancer patients whose tumors express high levels of the protein CD24 have worse prognoses than patients with lower CD24. A University of Colorado Cancer Center study published today in the Proceedings of the National Academy of Sciences shows that CD24 expression may depend on androgens - and that anti-androgen therapies like those currently used to treat prostate cancer may benefit bladder cancer patients.

25 Sep 2012

Marijuana and testicular cancer: an interview with Victoria Cortessis

This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).

24 Sep 2012

Glucocorticoids can thwart androgen receptor activity and regulate fat storage

In the body's ongoing effort to maintain a healthy weight, an arsenal of cellular proteins called androgen receptors is critical for blocking fat accumulation. Now researchers reporting in the September issue of the Cell Press Journal Chemistry & Biology have discovered that naturally occurring steroids called glucocorticoids can thwart the receptors' activity, ultimately encouraging fat buildup.

21 Sep 2012

Adolescent menstrual disorders linked to hyperandrogenemia

Menstrual disorders in adolescence are associated with an increased risk for hyperandrogenemia, research shows.

19 Sep 2012

Alendronate decreases BMD loss in prostate cancer

Weekly administration of oral biphosphonate alendronate could reduce loss of bone mineral density in prostate cancer patients who start androgen-deprivation therapy, show study findings.

19 Sep 2012

Power of taxane-based chemotherapy drugs may be potentially underestimated

The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.

18 Sep 2012

Intermittent hormone therapy effective for prostate cancer patients

Intermittent androgen deprivation is as effective as continuous therapy for men with rising prostate-specific antigen levels after primary or salvage radiotherapy, say researchers who believe the break from treatment improves quality of life.

10 Sep 2012

Study finds sex differences in vision between men and women

The way that the visual centers of men and women's brains works is different, finds new research published in BioMed Central's open access journal Biology of Sex Differences. Men have greater sensitivity to fine detail and rapidly moving stimuli, but women are better at discriminating between colors.

4 Sep 2012

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

30 Aug 2012